Biased by design? Clinical trials and patient benefit in oncology

References

• Naci H , DavisC, SavovićJet al. Design characteristics, risk of bias, and reporting of randomised controlled trials supporting approvals of cancer drugs by European Medicines Agency, 2014–16: cross sectional analysis. BMJ366, l5221 (2019).
   PubMedGoogle Scholar
• Downing NS , AminawungJA, ShahND, KrumholzHM, RossJS. Clinical trial evidence supporting FDA approval of novel therapeutic agents, 2005–2012. JAMA311(4), 368–377 (2014).
   PubMed Web of Science ®Google Scholar
• Chen EY , RaghunathanV, PrasadV. An overview of cancer drugs approved by the US Food and Drug Administration based on the surrogate end point of response rate. JAMA Intern. Med.179(7), 915–921 (2019).
   PubMed Web of Science ®Google Scholar
• Yothers G . Toward progression-free survival as a primary end point in advanced colorectal cancer. J. Clin. Oncol.25(33), 5153–5154 (2007).
   PubMed Web of Science ®Google Scholar
• Kemp R , PrasadV. Surrogate endpoints in oncology: when are they acceptable for regulatory and clinical decisions, and are they currently overused?BMC Med.15(1), 1–7 (2017).
   PubMedGoogle Scholar
• Haslam A , HeySP, GillJ, PrasadV. A systematic review of trial-level meta-analyses measuring the strength of association between surrogate end points and overall survival in oncology. Eur. J. Cancer106, 196–211 (2019).
   PubMed Web of Science ®Google Scholar
• Kim C , PrasadV. Cancer drugs approved on the basis of a surrogate end point and subsequent overall survival: an analysis of 5 years of US Food and Drug Administration approvals. JAMA Intern. Med.175(12), 1992–1994 (2015).
   PubMed Web of Science ®Google Scholar
• Davis C , NaciH, GurpinarE, PoplavskaE, PintoA, AggarwalA. Availability of evidence of benefits on overall survival and quality of life of cancer drugs approved by European Medicines Agency: retrospective cohort study of drug approvals 2009–13. BMJ359, j4530 (2017).
   PubMed Web of Science ®Google Scholar
• Pease AM , KrumholzHM, DowningNS, AminawungJA, ShahND, RossJS. Postapproval studies of drugs initially approved by the FDA on the basis of limited evidence: systematic review. BMJ357, j1680 (2017).
   PubMedGoogle Scholar
• Cherny NI , SullivanR, DafniUet al. A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS). Ann. Oncol.26(8), 1547–1573 (2015).
   PubMed Web of Science ®Google Scholar
• Schuller Y , BiegstraatenM, HollakCEM, KlümpenH-J, Gispen-deWied CC, Stoyanova-BeninskaV. Oncologic orphan drugs approved in the EU – do clinical trial data correspond with real-world effectiveness?Orphanet J. Rare Dis.13(1), 214 (2018).
   PubMedGoogle Scholar
• Wild C , GrössmannN, BonannoPVet al. Utilisation of the ESMO-MCBS in practice of HTA. Ann. Oncol.27(11), 2134–2136 (2016).
   PubMed Web of Science ®Google Scholar
• Grössmann N , DelPaggio JC, WolfSet al. Five years of EMA-approved systemic cancer therapies for solid tumours-a comparison of two thresholds for meaningful clinical benefit. Eur. J. Cancer82, 66–71 (2017).
   PubMed Web of Science ®Google Scholar
• Tibau A , MoltoC, OcanaAet al. Magnitude of clinical benefit of cancer drugs approved by the US Food and Drug administration. J. Natl Cancer Inst.110(5), 486–492 (2018).
   PubMedGoogle Scholar
• Saluja R , ArcieroVS, ChengSet al. Examining trends in cost and clinical benefit of novel anticancer drugs over time. J. Oncol. Pract.14(5), JOP1700058 (2018).
   PubMed Web of Science ®Google Scholar
• Vivot A , JacotJ, ZeitounJ-D, RavaudP, CrequitP, PorcherR. Clinical benefit, price and approval characteristics of FDA-approved new drugs for treating advanced solid cancer, 2000–2015. Ann. Oncol.28(5), 1111–1116 (2017).
   PubMed Web of Science ®Google Scholar
• Gyawali B , BoucheG, PantziarkaP, KesselheimAS, SarpatwariA. Lung cancer survival gains: contributions of academia and industry. J. Law. Med. Ethics47(3), 465–467 (2019).
   PubMed Web of Science ®Google Scholar
• Saluja R , ArcieroVS, ChengSet al. Examining trends in cost and clinical benefit of novel anticancer drugs over time. J. Oncol. Pract.14(5), JOP1700058 (2018).
   PubMed Web of Science ®Google Scholar
• Grössmann N , DelPaggio JC, WolfSet al. Five years of EMA-approved systemic cancer therapies for solid tumours-a comparison of two thresholds for meaningful clinical benefit. Eur. J. Cancer82, 66–71 (2017).
   PubMed Web of Science ®Google Scholar
• FDA. . FDA approves niraparib for HRD-positive advanced ovarian cancer. (2019). www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-niraparib-hrd-positive-advanced-ovarian-cancer
   Google Scholar
• Pantziarka P , VerbaanderdC, SukhatmeVet al. ReDO_DB: the repurposing drugs in oncology database. Ecancermedicalscience12, 886 (2018). https://ecancer.org/journal/12/full/886-redo_db-the-repurposing-drugs-in-oncology-database.php
   PubMed Web of Science ®Google Scholar
• Kim C , PrasadV. Cancer drugs approved on the basis of a surrogate end point and subsequent overall survival: an analysis of 5 years of US Food and Drug Administration approvals. JAMA Intern. Med.175(12), 1992–1994 (2015).
   PubMed Web of Science ®Google Scholar
• Fojo T , MailankodyS, LoA. Unintended consequences of expensive cancer therapeutics - the pursuit of marginal indications and a me-too mentality that stifles innovation and creativity: the John Conley lecture. JAMA Otolaryngol. Head Neck Surg.140(12), 1225–1236 (2014).
   PubMed Web of Science ®Google Scholar
• Results reported from the Phase III ANNOUNCE trial of olaratumab in soft-tissue sarcoma - the ASCO post. www.ascopost.com/News/59688?utm_source=TrendMD&utm_medium=cpc&utm_campaign=Sarcoma_TrendMD_0
   Google Scholar
• Cherny NI , de VriesEGE, DafniUet al. Comparative assessment of clinical benefit using the ESMO-magnitude of clinical benefit scale version 1.1 and the ASCO value framework net health benefit score. J. Clin. Oncol.37(4), 336–349 (2019).
   PubMed Web of Science ®Google Scholar
• The Adaptive Platform Trials Coalition. . Adaptive platform trials: definition, design, conduct and reporting considerations. Nat. Rev. Drug Discov.18(10), 797–807 (2019).
   PubMed Web of Science ®Google Scholar
• Parmar MKB , CarpenterJ, SydesMR. More multiarm randomised trials of superiority are needed. Lancet384(9940), 283–284 (2014).
   PubMed Web of Science ®Google Scholar
• Woodcock J , LaVangeLM. Master protocols to study multiple therapies, multiple diseases, or both. N. Engl. J. Med.377(1), 62–70 (2017).
   PubMed Web of Science ®Google Scholar
• Pantziarka P . Scientific advice – is drug repurposing missing a trick?Nat. Rev. Clin. Oncol.14(8), 455–456 (2017).
   PubMed Web of Science ®Google Scholar
• EMA. . PRIME: priority medicines. (2019). www.ema.europa.eu/en/human-regulatory/research-development/prime-priority-medicines
   Google Scholar
• Neez E , HwangT, SahooSA, NaciH. European Medicines Agency’s Priority Medicines (PRIME) scheme at 2years: an evaluation of clinical studies supporting eligible drugs. Clin. Pharmacol. Ther. doi.10.1002/cpt.1669 (2019) [ Epub ahead of print].
   PubMed Web of Science ®Google Scholar
• Mullard A . PRIME time at the EMA. Nat. Rev. Drug Discov.16(4), 226–228 (2017).
   PubMed Web of Science ®Google Scholar
• Kondo H , HataT, ItoK, KoikeH, KonoN. The current status of Sakigake designation in Japan, PRIME in the European Union, and Breakthrough Therapy Designation in the United States. Ther. Innov. Regul. Sci.51(1), 51–54 (2017).
   PubMed Web of Science ®Google Scholar
• Tafuri G , LucasI, EstevãoSet al. The impact of parallel regulatory-health technology assessment scientific advice on clinical development. Assessing the uptake of regulatory and health technology assessment recommendations. Br. J. Clin. Pharmacol.84(5), 1013–1019 (2018).
   PubMed Web of Science ®Google Scholar
• Eichler H-G , EnzmannH, RasiG. Added therapeutic benefit and drug licensing. Nat. Rev. Drug Discov.18(9), 651–652 (2019).
   PubMed Web of Science ®Google Scholar